Alimera Sciences (ALIM) Sees 6M Common IPO Price of $15 - $17
Tweet Send to a FriendGet Alerts ALIM Hot Sheet
Trade ALIM Now!
Alimera Sciences (NASDAQ: ALIM) filed an amended registration statement with the U.S. Securities and Exchange Commission for an initial public offering of its common stock. The company plans on an initial offering of 6,000,000 shares of common stock. They see a price of $15 - $17 per common share. The company plans to list on the NASDAQ under the stock symbol "ALIM".
The offering is being made through Credit Suisse, Citi, Cowen and Company and Oppenheimer & Co.
Alimera Sciences is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. They are presently focused on diseases affecting the back of the eye, or retina, because we believe these diseases are not well treated with current therapies and represent a significant market opportunity.
The offering is being made through Credit Suisse, Citi, Cowen and Company and Oppenheimer & Co.
Alimera Sciences is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. They are presently focused on diseases affecting the back of the eye, or retina, because we believe these diseases are not well treated with current therapies and represent a significant market opportunity.
You May Also Be Interested In
- Evoke Pharma (EVOK) Files $24M IPO
- Ambit Biosciences (AMBI) IPO Opens Flat
- Constellium (CSTM) IPO Opens Lower
Create E-mail Alert Related Categories
IPOsRelated Entities
Credit Suisse, Citi, Cowen & Co
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
